Related Experiment Video
Updated: Jun 30, 2026

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
Published on: January 1, 2016
Beta-lactamase inhibitors: another approach to overcoming antimicrobial resistance
Abstract:
Beta-lactamase inhibitors in combination with a beta-lactam antimicrobial agent provide another approach to the treatment of infections caused by many bacteria resistant to commonly used agents. Currently two fixed combinations are commercially available. One is the oral preparation of amoxicillin and potassium clavulanate (Augmentin). The other is for intravenous therapy and combines ticarcillin and potassium clavulanate (Timentin). In vitro studies confirm that the combination of a beta-lactamase inhibitor and a beta-lactam can increase the activity of the beta-lactam to such important pathogens as S aureus, Klebsiella, H influenzae, Bacteroides spp and other bacteria which produce plasmid-mediated beta-lactamase. Clinical efficacy studies have demonstrated potential usefulness of these combinations particularly for therapy of suspected or proven infections caused by mixed aerobic and anaerobic bacteria. The combination of amoxicillin or ticarcillin with clavulanic acid can be used to improve cost-effectiveness of antimicrobial therapy if they replace regimens that use multiple drugs or drugs with a relatively high incidence of adverse reactions.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Development of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance

